TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

145 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

137 studies on the map

BOTOX® vs. XEOMIN® for Chronic Migraine — Naval Medical Center Camp Lejeune, JacksonvillePhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborVirtual tES Device Treatment for Parkinson's Disease Motor Symptoms — U LLC Headquarters, ClevelandA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleA Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery — University of Kentucky, LexingtonA Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Ki Health Partners LLC DBA New England Institute for Clinical Research, StamfordEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaA Study of Buntanetap in Participants With PD — University of Alabama at Birmingham, BirminghamRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US — MedStar Health: Neurology at McLean, McLeanEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — The Belinga Clinic, Fort SmithCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Children's Hospital of Philadelphia, PhiladelphiaUS Zamto-cel Autoimmune Diseases — Froedtert Hospital and the Medical College of Wisconsin, MilwaukeeDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandA Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease — Research Site 4, Redwood CityA Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease — Banner Sun Health Research Institute, Sun CityA Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease — Barrow Neurological Institute, PhoenixThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) — Climb Bio Investigative Site #100104, AllenA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Rehabilitation and Neurological Services /ID# 270782, HuntsvilleA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) — University of Colorado Anschutz Medical Campus, AuroraArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaA Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Xenoscience Inc, PhoenixTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease — Wallace Rheumatic Center, Beverly HillsRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonBAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus — Nationwide Children's, ColumbusA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Central Research Associates, LLC (CRA) dba Flourish Research, BirminghamPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) — Rehabilitation & Neurological Services /ID# 229969, HuntsvilleRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaA Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease — Collaborative Neuroscience Network - CNS, Los AlamitosEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) — Life Clinical Trials - Colonial Drive - Margate /ID# 276050, MargateSAD Study in Patients With Parkinson's Disease and Motor Fluctuations — Rocky Mountain Clinical Research, EnglewoodTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeEffectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines — Advocate Christ Medical Center Emergency Department, Oak LawnREACT-01: Reversing Autoimmunity Through Cell Therapy — Seattle Children's Hospital, SeattleCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanCortical Electrophysiology of Response Inhibition in Parkinson's Disease — Emory University Hospital, AtlantaAlnuctamab for Refractory SLE (LATTE Study) — Icahn School of Medicine at Mount Sinai, New YorkPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaA Pilot Study of In-lab Dynamic Standing in Parkinson's Disease — Domino's Farms, Ann ArborFirst-in-Human Single and Multiple Dose of HL-400 — Pharmaron CPC, Inc., BaltimoreUsing taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease — Wellness, Health and Research Facility at UAB, BirminghamSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants — GSK Investigational Site, ScottsdaleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesA Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache — Maimonides Medical Center, BrooklynEnrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. — UPMC Presbyterian Hospital, PittsburghA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease — Mayo Clinic, PhoenixDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonThis Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. — Cornell University Weill Medical College, New YorkA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) — Pinnacle Research Group /ID# 278677, AnnistonA Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine — Hope Clinical Research, Canoga ParkDouble-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — National Institutes of Health Clinical Center, BethesdaBOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease — Cleveland Clinic, ClevelandStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Central Research Associates /ID# 260161, BirminghamEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications — Mayo Clinic in Arizona, PhoenixA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamA Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — University of Alabama at Birmingham, BirminghamTransplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) — University of California, San Diego, La JollaEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiOpen-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. — IRIS Research and Development, LLC, PlantationProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las VegasA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Sl0044 50058, AvondaleStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants — Research Site, BirminghamA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Mayo Clinic Hospital, PhoenixAutologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies — University of Kentucky, LexingtonStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La PalmaA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenA Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease — Austin Clinic PPD, AustinrTMS to Improve Cognition in Parkinson's — Jesse Brown VA Medical Center, Chicago, IL, Chicago[18F]F-DOPA Imaging in Patients With Autonomic Failure — Vanderbilt University Medical Center, NashvilleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — AARA Clinical Research, AvondalePimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis — Southern Arizona VA Health Care System, Tucson, AZ, TucsonA Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's — Northwestern University, EvanstonA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine — Yale-New Haven Children's Hospital - PIN, New HavenClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine — Yale University School of Medicine, New HavenTreating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons — Massachusetts General Hospital, BostonMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraUC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients — Medical University of South Carolina, CharlestonElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, RichmondA Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease — University of Kentucky Medical Center, LexingtonA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — Research Site, AnnistonA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — David S Hallegua MD A Professional Corporation, Beverly HillsPersonalized Real-Time DBS and PD Mechanisms — Cleveland Clinic, ClevelandEffects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure — Autonomic Dysfunction Center/ Vanderbilt University Medical Center, NashvilleHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteThe University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy — UAB Advanced Imaging Facility, BirminghamT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoPET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease — National Institutes of Health Clinical Center, BethesdaRandomized Study in Children and Adolescents With Migraine: Acute Treatment — Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, BirminghamRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamLong-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Perseverance Research Center, LLC, ScottsdaleQudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old — Upsher-Smith Clinical Trial Site #5, BirminghamGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghCharacterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases — Vanderbilt University Medical Center, NashvilleA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkEarly Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor — Lucile Packard Children's Hospital, Palo AltoComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Rehabilitation & Neurological Services /ID# 248517, HuntsvilleA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, FarmingtonA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. — Research Site, AnnistonComparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study — Northern Arizona Healthcare, FlagstaffDose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis — Mayo Clinic, RochesterA Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease — Site-049, BirminghamA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine — Arkansas Children's Hospital, Little RockA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, ChandlerA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, Chandler